Literature DB >> 23545517

Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients.

Esther Gonzalez, Jorge Rojas-Rivera, Natalia Polanco, Enrique Morales, José María Morales, Jesus Egido, Andres Amado, Manuel Praga.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23545517     DOI: 10.1097/TP.0b013e3182855565

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  14 in total

Review 1.  Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Panpan Cai; Xiaohong Tang; Wei Qin; Ling Ji; Zi Li
Journal:  Int Urol Nephrol       Date:  2016-01-09       Impact factor: 2.370

Review 2.  CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.

Authors:  A Prytuła; K Cransberg; A Raes
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

Review 3.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 4.  Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.

Authors:  Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino
Journal:  J Nephrol       Date:  2016-04-09       Impact factor: 3.902

Review 5.  Current evidence on vitamin D deficiency and kidney transplant: What's new?

Authors:  Gerardo Sarno; Riccardo Nappi; Barbara Altieri; Giacomo Tirabassi; Emanuele Muscogiuri; Gianmaria Salvio; Stavroula A Paschou; Aristide Ferrara; Enrico Russo; Daniela Vicedomini; Cerbone Vincenzo; Andromachi Vryonidou; Silvia Della Casa; Giancarlo Balercia; Francesco Orio; Paride De Rosa
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

Review 6.  Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review.

Authors:  Roberto Russo; Marinella Ruospo; Mario Cozzolino; Luca De Nicola; Andrea Icardi; Ernesto Paoletti; Sandro Mazzaferro
Journal:  J Nephrol       Date:  2014-07-11       Impact factor: 3.902

7.  Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Authors:  Matias Trillini; Monica Cortinovis; Piero Ruggenenti; Jorge Reyes Loaeza; Karen Courville; Claudia Ferrer-Siles; Silvia Prandini; Flavio Gaspari; Antonio Cannata; Alessandro Villa; Annalisa Perna; Eliana Gotti; Maria Rosa Caruso; Davide Martinetti; Giuseppe Remuzzi; Norberto Perico
Journal:  J Am Soc Nephrol       Date:  2014-09-05       Impact factor: 10.121

Review 8.  Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system.

Authors:  Domenico Santoro; Daniela Caccamo; Silvia Lucisano; Michele Buemi; Katerina Sebekova; Daniel Teta; Luca De Nicola
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411

Review 9.  Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

Authors:  Agnieszka Prytuła; Karlien Cransberg; Ann Raes
Journal:  Pediatr Nephrol       Date:  2018-07-30       Impact factor: 3.714

Review 10.  Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Authors:  Maria Vanessa Perez-Gomez; Maria Dolores Sanchez-Niño; Ana Belen Sanz; Catalina Martín-Cleary; Marta Ruiz-Ortega; Jesus Egido; Juan F Navarro-González; Alberto Ortiz; Beatriz Fernandez-Fernandez
Journal:  J Clin Med       Date:  2015-06-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.